Gene therapy for canine cancer: Clinical results

Canine Behavior, Classification and Diseases

Volumn , Issue , 2012, Pages 37-56

  Glikin, Gerardo C ^a   Finocchiaro, Liliana M E ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84869239424     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (42)

1. Alexander AN, Huelsmeyer MK, Mitzey A, Dubielzig RR, Kurzman ID, MacEwen EG, Vail DM. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma. Cancer Immunol Immunother. 2006, 55: 433-442.
2. Bergman PJ, Camps-Palau MA, McKnight JA, Leibman NF, Craft DM, Leung C, Liao J, Riviere I, Sadelain M, Hohenhaus AE, et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine. 2006; 24: 4582-4585.
3. Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J, Craft D, Wulderk M, Jeffers Y, Sadelain M, Hohenhaus AE, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin. Cancer Res. 2003; 9: 1284-1290.
4. Bianco SR, Sun J, Fosmire SP, Hance K, Padilla ML, Ritt MG, Getzy DM, Duke RC, Withrow SJ, Lana S, Matthiesen DT, et al. Enhancing antimelanoma immune responses through apoptosis. Cancer Gene Ther. 2003; 10: 726-736.
5. Bodles-Brakhop AM, Brown PA, Pope MA, Draghia-Akli R. Double-blinded, Placebo-controlled plasmid GHRH trial for cancer-associated anemia in dogs. Mol. Ther. 2008; 16: 862-70.
6. Casal M, Haskins M. Large animal models and gene therapy. Eur. J. Hum. Genet. 2006; 14: 266-272.
7. Chauvet AE, Kesava PP, Goh CS, Badie B. Selective intraarterial gene delivery into a canine meningioma. J. Neurosurg. 1998; 88: 870-873.
8. Dow S, Elmslie R, Kurzman I, MacEwen G, Pericle F, Liggitt D. Phase I study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases. Hum. Gene Ther. 2005; 16: 937-946.
9. Dow SW, Elmslie RE, Willson AP, Roche L, Gorman C, Potter TA. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J. Clin. Invest. 1998; 101: 2406-2414.
10. Draghia-Akli R, Hahn KA, King GK, Cummings KK, Carpenter RH. Effects of plasmid-mediated growth hormone-releasing hormone in severely debilitated dogs with cancer. Mol. Ther. 2002; 6: 830-836.
11. Dumey N, Mongiat-Artus P, Devauchelle P, Lesourd A, Cotard JP, Le Duc A, Marty M, Cussenot O, Cohen-Haguenauer O. In vivo retroviral mediated gene transfer into bladder urothelium results in preferential transduction of tumoral cells. Eur. Urol. 2005; 47: 257-263.
12. Ehrhart N. Soft-tissue sarcomas in dogs: a review. J. Am. Anim. Hosp. Assoc. 2005; 41: 241-246.
13. Finocchiaro LME, Fiszman GL, Karara AL, Glikin GC. Suicide gene and cytokines combined non viral gene therapy for canine spontaneous melanoma. Cancer Gene Ther. 2008; 15: 165-172.
14. Finocchiaro LME, Glikin GC. Cancer gene therapy in large animals. In New Gene Therapy and Cancer Research, W.B. Gustafsson (Ed.). Nova Science Publishers, Inc. (New York, U.S.A.). pp. 279-292 (2008). ISBN: 1-60021-969-1.(b)
15. Finocchiaro LME, Glikin GC. Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma. Gene Ther. 2008; 15: 267-276.(a)
16. Finocchiaro LME, Spector A, Rossi UA, Gil-Cardeza ML, Suarez JL, Riveros MD, Villaverde MS, Glikin GC. The potential of suicide plus immune gene therapy for treating osteosarcoma: the experience on canine veterinary patients. In Sarcoma: Symptoms, Causes and Treatments. E.J. Butler (Ed.). Nova Science Publishers, Inc. (New York, U.S.A.), (2012). ISBN: 978-1-62100-362-5. In press.
17. Finocchiaro, LME, Villaverde, MS, Gil-Cardeza, ML, Riveros, MD, Glikin, GC. Cytokine-enhanced vaccine and interferon-ß plus suicide gene as combined therapy for spontaneous canine sarcomas. Res. Vet. Sci. 2011, 91, 230-234.
18. Grosenbaugh DA, Leard AT, Bergman PJ, Klein MK, Meleo K, Susaneck S, Hess PR, Jankowski MK, Jones PD, Leibman NF et al. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am. J. Vet. Res. 2011; 72: 1631-8.
19. Gyorffy S, Rodriguez-Lecompte JC, Woods JP, Foley R, Kruth S, Liaw PC, Gauldie J. Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen. J. Vet. Intern. Med. 2005; 19: 56-63.
20. Hansen K, Khanna C. Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur. J. Cancer. 2004; 40: 858-880.
21. Hogge GS, Burkholder JK, Culp J, Albertini MR, Dubielzig RR, Keller ET, Yang NS, MacEwen EG. Development of human granulocyte-macrophage colony-stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancer. Hum. Gene Ther. 1998; 9: 1851-1861.
22. Kamstock D, Guth A, Elmslie R, Kurzman I, Liggitt D, Coro L, Fairman J, Dow S Liposome-DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma. Cancer Gene Ther. 2006; 13: 306-317.
23. Lawman M, Eidizadeh S, Selmon C, Kane C, Xigacos L, Kaufman L, Shaw N, Lawman P. Anti-tumor response induced by autologous cancer vaccine in canine lymphoma. Cancer Ther. 2008, 6: 827-840
24. Liao JC, Gregor P, Wolchok JD, Orlandi F, Craft D, Leung C, Houghton AN, Bergman PJ. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun. 2006; 6: 8.
25. MacEwen EG, Kurzman ID, Vail DM, Dubielzig RR, Everlith K, Madewell BR, Rodriguez CO Jr, Phillips B, Zwahlen CH, Obradovich J et al. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. Clin. Cancer Res. 1999; 5: 4249-4258)
26. Manley CA, Leibman NF, Wolchok JD, Rivière IC, Bartido S, Craft DM, Bergman PJ. Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs. J. Vet. Intern. Med. 2011; 25: 94-99.
27. Mayer MN, Grier CK. Palliative radiation therapy for canine osteosarcoma. Can. Vet. J. 2006; 47: 707-709.
28. Ohlfest JR, Freese AB, Largaespada DA. Nonviral vectors for cancer gene therapy: prospects for integrating vectors and combination therapies. Curr. Gene Ther. 2005; 5: 629-641.
29. Paoloni MC, Khanna C. Comparative oncology today. Vet. Clin. North Am. Small Anim. Pract. 2007; 37: 1023-1032.
30. Peruzzi D, Gavazza A, Mesiti G, Lubas G, Scarselli E, Conforti A, Bendtsen C, Ciliberto G, La Monica N, Aurisicchio L. A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma. Mol. Ther. 2010; 18: 1559-67.
31. Pluhar GE, Grogan PG, Seiler C, Goulart M, Santacruz KS, Carlson C, Chen W, Olin MR, Lowenstein PR, Castro MG, Haines SJ, Ohlfest JR. Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy. Vaccine 2010; 28: 3371-3378.
32. Porrello A, Cardelli P, Spugnini EP. Pet models in cancer research: general principles. J. Exp. Clin. Cancer Res. 2004; 23: 181-193.
33. Quintin-Colonna F, Devauchelle P, Fradelizi D, Mourot B, Faure T, Kourilsky P, Roth C, Mehtali M. Gene therapy of spontaneous canine melanoma and feline fibrosarcoma by intratumoral administration of histoincompatible cells expressing human interleukin-2. Gene Ther. 1996; 3: 1104-1112.
34. Reed SD, Fulmer A, Buckholz J, Zhang B, Cutrera J, Shiomitsu K, Li S. Bleomycin/ interleukin-12 electrochemogene therapy for treating naturally occurring spontaneous neoplasms in dogs. Cancer Gene Ther. 2010; 17: 457-64.
35. Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL, et al. Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 1990; 323: 570-578.
36. Sorenmo KU, Krick E, Coughlin CM, Overley B, Gregor TP, Vonderheide RH, Mason NJ. CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma. PLoS One. 2011; 6: e24167.
37. Thamm DH, Kurzman ID, MacEwen EG, Feinmehl R, Towell TL, Longhofer SL, Johnson CM, Geoly FJ, Stinchcomb DT. Intralesional lipid-complexed cytokine/superantigen immunogene therapy for spontaneous canine tumors. Cancer Immunol Immunother. 2003; 52: 473-480.
38. Turek MM, Thamm DH, Mitzey A, Kurzman ID, Huelsmeyer MK, Dubielzig RR, Vail DM. Human granulocyte-macrophage colony-stimulating factor DNA cationic-lipid complexed autologous tumour cell vaccination in the treatment of canine B-cell multicentric lymphoma. Vet. Comp. Oncol. 2007; 5: 219-231.
39. U'Ren LW, Biller BJ, Elmslie RE, Thamm DH, Dow SW. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. J. Vet. Intern. Med. 2007; 21:113-120.
40. Vail DM, MacEwen EG. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest. 2000; 18: 781-792.
41. Vassaux G, Groot-Wassink T. In vivo noninvasive imaging for gene therapy. J. Biomed. Biotechnol. 2003: 92-101.
42. von Euler H, Sadeghi A, Carlsson B, Rivera P, Loskog A, Segall T, Korsgren O, Tötterman TH. Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma. J. Immunother. 2008, 31: 377-384.